Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment
- PMID: 24923811
- PMCID: PMC4265308
- DOI: 10.1002/pds.3660
Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment
Abstract
Objectives: We evaluated changes in oral diabetes mellitus medication adherence and persistence, as well as glycemic control for the year prior to breast cancer (BC) diagnosis (Year -1), during BC treatment, and in subsequent years.
Methods: Cohort study of 4216 women diagnosed with incident early stage (I and II) invasive BC from 1990-2008, enrolled in Group Health Cooperative. Adherence was measured in prevalent users at baseline (N = 509), during treatment, and 1-3 years post-diagnosis using medication possession ratio (MPR), % adherent (MPR ≥0.80) and discontinuation rates. Laboratory data on glycosylated hemoglobin (HbA1c ) was obtained for the corresponding periods.
Results: Compared with Year -1, mean MPR for metformin/sulfonylureas (0.86 vs 0.49, p < 0.001) and % adherent (75.3% vs 24.6%, p < 0.001) declined during BC treatment. MPR and % adherent rose slightly during Years 1-3 post-diagnosis but never returned to baseline. Discontinuation rates increased from treatment to Year +1 (59.3% vs 75.6%, p < 0.001) and remained elevated during subsequent observation periods. Compared with baseline, increased HbA1c (7.0% vs 7.4%, p = 0.001) and % women with high HbA1c >7.0% (34.9% vs 51.1%, p < 0.001) coincided with decreased adherence.
Conclusion: Diabetes mellitus medication adherence declined following BC diagnosis, whereas discontinuation rates were relatively stable but poor overall. The proportion of adherent users increased only marginally following treatment, whereas the proportion of women meeting goals for HbA1c decreased considerably. These data support the hypothesis that adherence and subsequent glycemic control are sensitive to BC diagnosis and treatment. Confirmatory studies in other settings, on reasons for reduced adherence post-cancer diagnosis, and on subsequent indicators of glycemic control are warranted.
Keywords: breast cancer; diabetes mellitus; glycemic control; medication adherence; pharmacoepidemiology.
Copyright © 2014 John Wiley & Sons, Ltd.
Conflict of interest statement
Disclosure: The authors have no conflicts of interest to disclose.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4265308/bin/nihms613284f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4265308/bin/nihms613284f2.gif)
Similar articles
-
Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment.Breast Cancer Res Treat. 2013 Feb;138(1):225-33. doi: 10.1007/s10549-013-2424-2. Epub 2013 Jan 29. Breast Cancer Res Treat. 2013. PMID: 23358904 Free PMC article.
-
A retrospective database analysis of neuropathic pain and oral antidiabetic medication use and adherence among Texas adults with type 2 diabetes enrolled in Medicaid.Clin Ther. 2012 Mar;34(3):605-13. doi: 10.1016/j.clinthera.2012.02.007. Epub 2012 Mar 3. Clin Ther. 2012. PMID: 22386828
-
Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.Cardiovasc Diabetol. 2013 Mar 23;12:48. doi: 10.1186/1475-2840-12-48. Cardiovasc Diabetol. 2013. PMID: 23522121 Free PMC article. Clinical Trial.
-
Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis.Curr Med Res Opin. 2012 Jun;28(6):969-77. doi: 10.1185/03007995.2012.684045. Epub 2012 May 3. Curr Med Res Opin. 2012. PMID: 22494018 Review.
-
Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.Clin Ther. 2007;29 Spec No:1236-53. Clin Ther. 2007. PMID: 18046925 Review.
Cited by
-
Analysis of the Incidence of Type 2 Diabetes, Requirement of Insulin Treatment, and Diabetes-Related Complications among Patients with Cancer.Cancers (Basel). 2023 Feb 8;15(4):1094. doi: 10.3390/cancers15041094. Cancers (Basel). 2023. PMID: 36831436 Free PMC article.
-
Ethnic disparities in medication adherence? A systematic review examining the association between ethnicity and antidiabetic medication adherence.PLoS One. 2023 Feb 22;18(2):e0271650. doi: 10.1371/journal.pone.0271650. eCollection 2023. PLoS One. 2023. PMID: 36812177 Free PMC article.
-
Adherence to cardiovascular disease risk factor medications among patients with cancer: a systematic review.J Cancer Surviv. 2023 Jun;17(3):595-618. doi: 10.1007/s11764-022-01212-0. Epub 2022 May 17. J Cancer Surviv. 2023. PMID: 35578150 Free PMC article. Review.
-
Characterizing Beliefs About Breast Cancer and Comorbid Diabetes After Cancer Treatment.Oncol Nurs Forum. 2022 Mar 1;49(2):158-166. doi: 10.1188/22.ONF.158-166. Oncol Nurs Forum. 2022. PMID: 35191897 Free PMC article.
-
Providers' mediating role for medication adherence among cancer survivors.PLoS One. 2021 Nov 29;16(11):e0260358. doi: 10.1371/journal.pone.0260358. eCollection 2021. PLoS One. 2021. PMID: 34843550 Free PMC article.
References
-
- American Cancer Society. Breast Cancer Facts & Figures 2013-2014. Atlanta: American Cancer Society, Inc.; 2013.
-
- Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. The American journal of medicine. 2005;118(Suppl 5A):27S–34S. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical